Serum Long Noncoding RNA H19 and CKD Progression in IgA Nephropathy

He, Lijie; Wang, Hanmin; He, Peng; Jiang, Yali; Ma, Feng; Wang, Jing; Hu, Jinping

doi:10.1007/s40620-022-01536-1

Cited by 4 publications

(4 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, lncRNA H19 may regulate fibrosis in a context-dependent manner, meaning that its exact effect on fibrosis needs further investigation using different models. Our previous study found that lncRNA H19 levels were decreased in the serum of patients with chronic kidney diseases and lncRNA H19 reduction was closely related to renal tubulointerstitial fibrosis [ 28 ]. In this work, we further investigated the exact role of lncRNA H19 in renal tubulointerstitial fibrosis using the UUO mouse model in vivo .…”

Section: Discussionmentioning

confidence: 99%

“…lncRNA H19 serves as a key determinant in fibrosis-related disorders [ 27 ]. Our previous findings have documented that serum lncRNA H19 levels are decreased in patients with chronic kidney disorders and lncRNA H19 reduction is closely correlated with renal tubulointerstitial fibrosis [ 28 ]. Nonetheless, the precise function and mechanism of lncRNA H19 in renal tubulointerstitial fibrosis are not fully comprehended.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Up-regulation of long non-coding RNA H19 ameliorates renal tubulointerstitial fibrosis by reducing lipid deposition and inflammatory response through regulation of the microRNA-130a-3p/long-chain acyl-CoA synthetase 1 axis

Jiang,

Ma,

Wang

et al. 2024

Non-coding RNA Research

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Up-regulation of long non-coding RNA H19 ameliorates renal tubulointerstitial fibrosis by reducing lipid deposition and inflammatory response through regulation of the microRNA-130a-3p/long-chain acyl-CoA synthetase 1 axis

Jiang,

Ma,

Wang

et al. 2024

Non-coding RNA Research

Self Cite

View full text Add to dashboard Cite

“…Moreover, lncRNA H19 had a protective role for prognosis in IgAN. Higher expression levels of H19 suggested better renal outcome in IgAN patients [83]. LncRNA PTTG3P was upregulated in IgAN samples and urinary of IgAN patients.…”

Section: Lncrnas Regulate Iga1 Glycosylationmentioning

confidence: 90%

Deciphering roles of protein post-translational modifications in IgA nephropathy progression and potential therapy

Sun,

Shi,

Zhang

et al. 2024

Aging

View full text Add to dashboard Cite

Immunoglobulin A nephropathy (IgAN), one type of glomerulonephritis, displays the accumulation of glycosylated IgA in the mesangium. Studies have demonstrated that both genetics and epigenetics play a pivotal role in the occurrence and progression of IgAN. Post-translational modification (PTM) has been revealed to critically participate in IgAN development and progression because PTM dysregulation results in impaired degradation of proteins that regulate IgAN pathogenesis. A growing number of studies identify that PTMs, including sialylation, o-glycosylation, galactosylation, phosphorylation, ubiquitination and deubiquitination, modulate the initiation and progression of IgAN. Hence, in this review, we discuss the functions and mechanisms of PTMs in regulation of IgAN. Moreover, we outline numerous compounds that govern PTMs and attenuate IgAN progression. Targeting PTMs might be a useful strategy to ameliorate IgAN.

show abstract

“…Intriguingly, it has been shown that IGF2 and lncRNA H19 compete for the same binding enhancer, and the lncRNA H19-IGF2 imprinted gene area is likely linked to an increased risk of having compromised renal function (IRF) ( 166 ). Otherwise, renal clear cell carcinoma, Wilms tumors, and renal cell carcinoma are all influenced by the interaction between lncRNA H19 and IGF2 ( 167 – 169 ).…”

Section: Role Of Lncrna H19 In Nondiabetic Kidney Diseasementioning

confidence: 99%

LncRNA H19: a novel player in the regulation of diabetic kidney disease

Wu,

Huang

2023

Front. Endocrinol.

View full text Add to dashboard Cite

Diabetic kidney disease (DKD), one of the most severe complications of diabetes mellitus (DM), has received considerable attention owing to its increasing prevalence and contribution to chronic kidney disease (CKD) and end-stage kidney disease (ESRD). However, the use of drugs targeting DKD remains limited. Recent data suggest that long non-coding RNAs (lncRNAs) play a vital role in the development of DKD. The lncRNA H19 is the first imprinted gene, which is expressed in the embryo and down-regulated at birth, and its role in tumors has long been a subject of controversy, however, in recent years, it has received increasing attention in kidney disease. The LncRNA H19 is engaged in the pathological progression of DKD, including glomerulosclerosis and tubulointerstitial fibrosis via the induction of inflammatory responses, apoptosis, ferroptosis, pyroptosis, autophagy, and oxidative damage. In this review, we highlight the most recent research on the molecular mechanism and regulatory forms of lncRNA H19 in DKD, including epigenetic, post-transcriptional, and post-translational regulation, providing a new predictive marker and therapeutic target for the management of DKD.

show abstract

Serum Long Noncoding RNA H19 and CKD Progression in IgA Nephropathy

Cited by 4 publications

References 50 publications

Up-regulation of long non-coding RNA H19 ameliorates renal tubulointerstitial fibrosis by reducing lipid deposition and inflammatory response through regulation of the microRNA-130a-3p/long-chain acyl-CoA synthetase 1 axis

Up-regulation of long non-coding RNA H19 ameliorates renal tubulointerstitial fibrosis by reducing lipid deposition and inflammatory response through regulation of the microRNA-130a-3p/long-chain acyl-CoA synthetase 1 axis

Deciphering roles of protein post-translational modifications in IgA nephropathy progression and potential therapy

LncRNA H19: a novel player in the regulation of diabetic kidney disease

Contact Info

Product

Resources

About